KIM DENNIS D 4
4 · CymaBay Therapeutics, Inc. · Filed Apr 17, 2023
Insider Transaction Report
Form 4
KIM DENNIS D
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-17$4.37/sh+112,219$490,397→ 132,219 total - Exercise/Conversion
Common Stock
2023-04-13$4.37/sh+7,781$34,003→ 27,781 total - Sale
Common Stock
2023-04-17$9.54/sh−112,219$1,070,536→ 20,000 total - Sale
Common Stock
2023-04-13$8.98/sh−7,781$69,880→ 20,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-13−7,781→ 282,119 totalExercise: $4.37Exp: 2031-05-16→ Common Stock (7,781 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-17−112,219→ 169,900 totalExercise: $4.37Exp: 2031-05-16→ Common Stock (112,219 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter.